drugset / Trial / NCT06045195
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
Timeline
- Start
- 2025-08
- Primary completion
- 2027-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |